Mind Medicine Financials

Mind Medicine Stock Summary

Mind Medicine competes with Stratasys, Grupo Televisa, Pinduoduo, US Silica, and Digi International. Mind Medicine Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. Mind Medicine operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 22 people.

Mind Medicine Key Financial Ratios

Generally speaking, Mind Medicine's financial ratios allow both analysts and investors to convert raw data from Mind Medicine's financial statements into concise, actionable information that can be used to evaluate the performance of Mind Medicine over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Mind Medicine reports annually and quarterly.

Mind Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Mind Medicine's current stock value. Our valuation model uses many indicators to compare Mind Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mind Medicine competition to find correlations between indicators driving Mind Medicine's intrinsic value. More Info.Mind Medicine is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Mind Medicine by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mind Medicine's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mind Medicine's earnings, one of the primary drivers of an investment's value.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Mind Medicine information on this page should be used as a complementary analysis to other Mind Medicine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

If you are still planning to invest in Mind Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mind Medicine's history and understand the potential risks before investing.